Connect with us

Hi, what are you looking for?

Jewish Business News


Neuromagen Receives FDA Orphan Drug to Slow Progression of ALS

The Israeli Neuromagen’s pipeline includes treatments for neurodegenerative diseases ALS, Alzheimer’s, type 1 diabetes, fertility, and cardiovascular illnesses.

Neuromagen Pharma recieves FDA aprovel for drug Slow the Progression of ALS
Treatments for ALS: A man with ALS communicates by pointing to letters and words using a head-mounted laser pointer. Credit Fezcat

Israeli Neuromagen Pharma Ltd., a developer of drugs to treat degenerative and senescence-associated diseases, has received FDA Orphan Drug Designation for its lead drug candidate, AGS-499, which has demonstrated significant efficacy in delaying the onset and progression of amyotrophic lateral sclerosis (ALS) (Amyotrophic Lateral Sclerosis).

The Orphan Drug Designation program grants orphan designation to medicines and biologics intended to treat, prevent, or diagnose a disease or condition that affects fewer than two hundred thousand persons in the United States. This designation grants Neuromagen seven years of marketing exclusivity for AGS-499 following ALS therapy approval and launch.

AGS-499 has remarkable neurogenesis and neuroprotective properties in neuronal cells from ALS patients and dose- and time-dependent delayed start and development of ALS in mice models.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

The AGS series of Neuromagen’s patent-protected medications contain compounds that activate telomerase reverse transcriptase (TERT).

Telomerase is a crucial enzyme for cell survival and longevity since it inhibits telomere shortening and regulates cell senescence. The medications shown preclinical effectiveness for ALS, neurological illnesses (Alzheimer’s), Diabetes, fertility, and cardiovascular problems.

Neuromagen was founded in 2021 by Prof. Esther Priel, the director of Ben-Gurion University of the Negev’s Laboratory for Nucleic Acids Topology.

Prof. Priel is thrilled that the FDA designation will give financial and regulatory benefits as well as unique protection for the commercialization of AGS-499. We feel this therapy strategy has enormous potential and look forward to initiating clinical studies for AGS-499 as we continue to build our pipeline.

“The FDA Orphan Treatment Designation is a critical milestone for this possible ALS drug development,” says Gil Ben-Menachem, Neuromagen’s founder and chief executive officer.

Neuromagen will develop the ALS medicine internally and is exploring partnerships with pharmaceutical companies in other therapeutic areas.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.